If it hasn’t happened yet, just wait: the day will come when you have to use a larger font on the computer or hold the phone farther away to read a message. That frustrating condition, presbyopia, is a $3-5 billion market with limited non-surgical treatment options. LENZ Therapeutics is one company on a path to change that.

In this podcast, president and CEO Eef Schimmelpennink speaks with host Ehsan Sadri, MD, about the progress of the company’s lead program, aceclidine. The drop is designed to restore loss of near vision without triggering ciliary muscles, and it produced promising Phase II data.

As the company moves toward Phase III clinical trials, fresh off emerging from stealth mode with a $47 million Series A financing from Versant Ventures and RA Capital Management, Schimmelpennink reveals his larger picture for LENZ — without reaching for the reading glasses. 

Listen to the podcast to discover: 

• Schimmelpennink’s views on the influence on compounding pharmacies for presbyopia treatments.
• The impact of Allergan’s miotics on this space.
• The potential benefits of these treatments for optometrists and ophthalmologists.
• What attracted Schimmelpennink to Presbyopia Therapies (now LENZ Therapeutics).
• What’s next for LENZ in the presbyopia market and beyond.